Equipoise calibration of clinical trial design

Fabio Rigat, Phd [\(fabio.rigat@astrazeneca.com\)](mailto:fabio.rigat@astrazeneca.com)

Abstract

Statistical methods for clinical trial design are currently unable to rely on a sufficiently precise and general definition of what is an adequately powered study. Operationally, this definition is needed to ensure an alignment by design between statistical significance and clinical interpretability.

To address this gap, this paper shows how to calibrate randomised trial designs to establishing strong clinical equipoise imbalance. Among several equipoise models, the least informed population distribution of the pre-trial odds of the design hypotheses is recommended here as the most practical calibrator.

Under this model, primary analysis outcomes of common phase 3 superiority designs are shown to provide at least 90% evidence of equipoise imbalance. Designs carrying 95% power at 5% false positive rate are shown to demonstrate even stronger equipoise imbalance, providing an operational definition of a robustly powered study. Equipoise calibration is then applied to design of clinical development plans comprising randomised phase 2 and phase 3 studies. Development plans using oncology clinical endpoints are shown to provide strong equipoise imbalance when positive outcomes are observed in phase 2 and in phase 3. Establishing equipoise imbalance on a statistical basis when a positive phase 2 is not confirmed in phase 3 is shown to require large sample sizes unlikely to be associated with clinically meaningful effect sizes.

Equipoise calibration is proposed as an effective clinical trial methodology ensuring that the statistical properties of clinical trial outcomes are clinically interpretable. Strong equipoise imbalance is achieved for designs carrying 95% power at 5% false positive rate, regardless of whether the primary outcome is positive or negative. Sponsors should consider raising power of their designs beyond current practice to achieve more conclusive results.

Keywords: clinical trial design, clinical equipoise, oncology, clinical development plans.

Introduction

The design and analysis of clinical trials are guided by harmonised principles developed over three decades [1], with further recent development in several areas including paediatric extrapolation, adaptive designs and the assessment of patient preferences [2-4]. An important goal of these principles is to ensure that the precision associated with positive trial results is sufficient to convey strong statistical evidence. However, precision per se is insufficient for a positive trial outcome to be practice-changing, because p-values and posterior probabilities do not necessarily map into clinically meaningful treatment effects [5]. This potential discrepancy between statistically significant and practically relevant results is partly imputable to the lack of an operational definition of what is an adequately powered study. To mitigate this gap, this paper articulates specific conditions under which a primary analysis outcome can be interpreted as representing strong clinical equipoise imbalance [6]. Sections 1 and 2 respectively introduce necessary statistical background and discuss three probabilistic representations of clinical equipoise for confirmatory trial design. Among these, the equipoise model based on the least amount of pre-trial information is motivated as the most widely applicable option. Under this model, positive trial outcomes carrying 90% cumulative power at 5% family-wise error rate (FWER) are shown to provide almost 95% equipoise imbalance in favour of the alternative hypothesis. Negative trial outcomes are shown to provide equally strong equipoise imbalance in favour of the null hypothesis if power can be meaningfully increased to 95%. Section 3 extends equipoise calibration to design of clinical development plans comprising one randomised phase 2 trial followed by one phase 3 confirmatory trial. The designs considered here use efficacy endpoints and data analysis methods commonly used to establish superiority of investigational treatments in oncology. Typical designs are shown to provide high overall levels of equipoise imbalance in favour of the combined phase 2 and phase 3 design hypotheses when positive trial outcomes are observed in both studies. Surprisingly, large increases in sample sizes are shown to be insufficient to providing strong equipoise imbalance in favour of the overall null hypothesis when a phase 3 trial fails to confirm a positive phase 2 outcome. The discussion examines the potential impact of equipoise calibration in practice, including instances when perfect pre-study equipoise is unlikely to hold. Minimal notation is used throughout, to foster critical appraisal by the broadest audience.

1. The post-study odds of the design hypotheses quantify clinical equipoise imbalance

The relation among conditional error probabilities, the pre-study odds of the design hypotheses and their post-study odds is presented in [7], further developing previous work [8]. Pre-study odds quantify the relative likelihood of the design null hypothesis H_0 versus the motivating trial hypothesis H_1 . Post-study odds quantify the change in the pre-study odds of the design hypotheses as the primary clinical trial outcome is observed, in absence of any other emerging evidence. Using standard probability calculus, post-study odds are defined as the product between pre-study odds and the likelihood ratio of the study outcome when respectively H_0 or H_1 is assumed true, as shown in equations (A.1) and (A.2) in the Appendix. Here the symbols + and – represent respectively a statistically positive or negative study outcome, and $p(+|H_0)$ and $p(+|H_1)$ are the associated false positive error rate and power. The symbols $r_{10}(+)$ and $r_{01}(-)$ in (A.1)-(A.2) represent the post-study odds respectively in favour of H_1 upon observing a positive study outcome and of H_0 when the study is negative.

For instance, a positive study outcome carrying 90% power at 5% false positive error rate increases the pre-trial odds of H_1 versus H_0 by a factor of 0.9/0.05 = 18. Likewise, a negative outcome at the same power and false positive error level increases the pre-trial odds of H_0 versus H_1 by a factor of $(1 - 0.05)/0.1 = 9.5$. The weight of evidence associated to a negative outcome here is roughly half as that of a positive outcome because the probability of false negatives is twice as large as that of false positives.

Of note, the clinical and statistical assumptions defining positive and negative study outcomes are unspecified in (A.1)-(A.2). For this general definition to be practically meaningful, the estimand framework [9] needs being appropriately implemented. Specific examples are provided here using oncology efficacy endpoints relying on established clinical response criteria [10-16]. In this context, a positive trial outcome is typically defined as a clinically meaningful and statistically significant difference between objective response rates (ORR), or between the progression free survival (PFS) or overall survival (OS) distributions observed in parallel trial arms. Also, two sources of uncertainty are combined in (A.1)-(A.2). The first source of uncertainty in (A.1)-(A.2) consists of the operational characteristics of trial designs, namely the theoretical frequencies of respectively positive or negative outcomes should the study be repeated under identical conditions when either H_0 or H_1 are assumed true. Sample size is a component of study power here, although this is not made explicit to keep notation simple. Ratios of "capital P " quantities in $(A.1)-(A.2)$ represent the relative likelihood about the truth of the design hypotheses available at design stage. This uncertainty component represents the pre-study evidence necessary in practice to defining a meaningful design, including primary endpoints and magnitude of effects defining the hypothesis H_1 . Population models of pre-study uncertainty representing clinical equipoise are discussed next.

2. Equipoise calibration of clinical trial design

Clinical equipoise is "a state of genuine uncertainty within the expert medical community about the preferred treatment" [6], primarily in relation to decision making in clinical practice. Equipoise is not required by ICH good clinical practice principles [17] and its relevance for trial design has been debated [18]. Recently, lack of equipoise was recognised as a driver of potential biases during clinical study conduct in oncology [19-20]. However, a mathematical definition of clinical equipoise has not yet been proposed, so that its application to design and interpretation of trial outcomes cannot rely yet on a set of clearly stated assumptions. A formal definition of clinical equipoise is proposed here, recognising that any practical model needs providing an acceptable representation of the clinical population uncertainty between at least two potential treatments. Under this definition, a positive study outcome is not only required to be highly unlikely if the null hypothesis were to be true, but it is also required to be unlikely under perfect pre-study equipoise. Hence, equipoise calibration entails an additional requirement compared to current design practice, by constraining the statistical definition of a positive study outcome within a clinically interpretable framework.

2.1 Three probabilistic models of clinical equipoise

The only survey published to date [21] quantifying pre-study uncertainty within an expert medical community suggests that odds of 2:1 do not convey robust equipoise imbalance. Formal elicitation methods [22-23] may be applied here to refining this empirical estimate based on larger survey samples. Weakness of the 2:1 odds is also substantiated by statistical modelling, which shows that odds of 3:1 are associated to barely significant p-values, and odds greater than 14:1 correspond to p-values smaller than 0.005 and are recommended as a basis for robust discovery claims [8]. Building on these results, the models explored here describe the population distribution of the pre-study odds using minimal assumptions, as a basis for design calibration. To this end, let

$$
P(H_1) := 1 - P(H_0), \tag{1}
$$

$$
P(H_0) \sim U(0,1). \tag{2}
$$

Equation (1) states that the pre-study evidence in favour of the design hypothesis is defined as the complement to any available evidence in favour of the null. Equation (2) states that, among all population frequency distributions suitable to describing pre-study uncertainty about the null hypothesis, the uniform distribution assumes the minimum amount of pre-study background as measured by information entropy [24] or, equivalently, by variance. Conditions (1)-(2) are sufficient to determining the analytical form of the population frequency distribution of the pre-study odds, with is Beta Prime with parameters $(1,1)$, hereby referred to as $BP(1,1)$. Figure 1 depicts the reverse cumulative distribution function (rCDF) of this equipoise model, alongside to those of two alternatives. Each of these curves represents the proportion of the expert medical population associated with pre-study odds greater than the values shown on the horizontal axis, according to each clinical equipoise model. The $BP(1,1)$ model, depicted in black in Figure 1, represents clinical equipoise as median population pre-study odds of 1:1, which are equally in favour or against the null hypothesis. Median pre-study equipoise is also implied by the $BP(0.5,0.5)$ model, depicted in red in Figure 1. Here the maximum entropy distribution (2) is replaced with a $Beta(0.5,0.5)$, motivated by invariance and asymptotic information arguments [25-26]. This equipoise model describes a polarised population within which pre-study confidence in H_0 is equally concentrated towards the extreme values 0 and 1. Model $BP(1,2)$, depicted in blue in Figure 1, replaces (2) with a $Beta(1,2)$ population distribution, which represents equipoise as average pre-study odds equal to 1:1. Applicability of each equipoise model for calibration of trial design is considered next.

2.2 Application of equipoise models to study design calibration

The population frequency of pre-study odds greater than any given value X on the horizonal axis in Figure 1 equals 1/(1+X) under the *BP*(1,1) equipoise model. For instance, under (1)-(2) the population frequency associated with pre-study odds greater than 1:1 in favour of H_1 is $1/(1+1) = 50\%$. Now, by (A.1) a positive outcome designed to carry 90% power at 5% false positive error rate demonstrates post-study odds in favour of H_1 equal to $0.9/0.05 = 18:1$ under perfect pre-study equipoise. Since the population frequency of pre-study odds greater or equal to the value 18 under (1)-(2) equals $1/(1+18) \approx 5.26\%$, a positive result carrying 90% power at 5% false positive rate demonstrates equipoise imbalance at the 94.74% percentile of the *BP*(1,1) pre-study odds distribution. More generally, if robust equipoise imbalance is defined by post-study odds greater or equal to the 95th percentile of the pre-study equipoise distribution, establishing robust equipoise imbalance under the *BP(1,2), BP(1,1)* and *BP(0.5,0.5)* models respectively requires post-study odds greater than 3.5:1, 19:1 and 161:1.

BetaPrime pre-study odds reverse cumulative distribution functions

Figure 1: reverse cumulative distribution functions (rCDFs) of three pre-study odds equipoise probability models. The BP(1,1) model, depicted in black, assumes that pre-study evidence in favour of the null hypothesis is uniformly distributed within the expert clinical population. The BP(0.5,0.5) model shown in red represents pre-study evidence concentrated towards extreme probability values $P(H_0) = 0$ or $P(H_0) = 1$. The BP(1,2) model shown in blue assumes weak evidence against the null *distribution. Clinical equipoise is represented as median pre-study odds of 1 by the BP(1,1) and BP(0.5,0.5) models, and by average pre-study odds of 1 by the BP(1,2) model.*

These numerical discrepancies show that none of the models depicted in Figure 1 can be prescriptive, because clinical equipoise admits multiple probabilistic representations leading to different post-study odds thresholds suitable to demonstrating strong equipoise imbalance. Model *BP(1,1)* is proposed here as the reference equipoise representation for trial design calibration for three reasons: first, this model assumes the least pre-study evidence, which maximises its range of potential applications. Second, the post-study odds associated to strong equipoise imbalance under the *BP(1,1)* model are no weaker than current practice for confirmatory trial design, unlike for the *BP(1,2)* model. Third, the *BP(0.5,0.5)* model is impractical because it requires post-study odds thresholds for demonstrating equipoise imbalance associated with extremely low false positive rates or extremely high power, which could lead to inappropriately small effect sizes being identified as strong clinical evidence. To demonstrate this point it suffices to examine what power would be required by each of the models in Figure 1 to define equipoise imbalance at the 95th pre-study population percentile. Using (A.1), the power required to achieve post study odds of 19:1 or above at 5% false positive rate under (1)-(2) is the solution to the inequality $p(+|H_1)/0.05 \ge 19$, that is $p(+|H_1) \ge$ 95%. This is a more conservative definition of "adequately powered study" compared to the

80%-90% power range currently used in practical design work. Conversely, if the *BP(1,2)* model were to be used to define an adequately powered study at 5% false positive rate, the required power would be $p(+|H_1)/0.05 \ge 3.5$ that is $p(+|H_1) \ge 17.5$ %, which would clearly lower clinical evidence standards compared to current practice. Finally, the *BP(0.5,0.5)* model cannot be used to design a clinical trial at 5% false positive rate, because the required power would be p (+| H_1)/0.05 ≥ 161 which does not admit a solution within the 0-100% range. The maximum false positive error rate that could be used to calibrate a study design under the *BP(0.5,0.5)* equipoise model is approximately 0.62% at power levels greater or equal to 99.9%. These extreme requirements would practically entail large sample sizes likely leading to inappropriately identifying small treatment effects as strong clinical evidence.

Design operational characteristics		Post-study odds	Pre-study equipoise	
False Positive rate	Power	in favour of H_1	model percentile	
10%		9	90%	
5%	90%	18	94.74%	
5%	95%	19	95%	
1%	99%	99	99%	

Table 1: operational characteristics of the trial outcome, posterior odds in favour of the design hypothesis from observation of a positive study outcome and associated (1,1) *pre-study equipoise model percentile.*

2.3 Does equipoise calibration change current study design practice? A case study

Table 1 suggests that application of equipoise calibration may have a small impact on power per se, compared to current design practices. However, an increase in power from 90% up to 95% would impact the strength of evidence provided by a negative study outcome, as demonstrated below.

Group sequential (GS) methods [27-28] control the family-wise error rate (FWER) of randomised clinical trials with multiple pre-planned analyses. The GS design is used here has one primary time-to-event (TTE) endpoint, assuming a median of 10 months in the SOC arm. Effect sizes are measures by hazard ratios (HR), following current practice. The design hypothesis H_1 : HR = 0.7 postulates that a relative risk reduction of 30% compared to SOC will be observed in the investigational arm, which is expected to provide 4 months increase in median TTE under exponential distributions. The O'Brien and Fleming (OBF) alpha spending function is used to distribute the overall false positive error probability between one interim analysis (IA) at 70% information fraction and, should this IA not be positive, the final analysis

(FA) at 42 months follow-up. At IA and at FA respectively 36% and 52% of study participants are expected to have experienced the event defining the primary endpoint across the two arms. This design represents assumptions commonly used when planning a confirmatory study in oncology, where the primary endpoint is typically progression free survival (PFS) or overall survival (OS). Table 2 shows that a positive trial outcome at 90% power here provides odds of at least 19.7:1 against the null, and a negative outcome provides odds of approximately 9.5:1 in favour of the null. These post-trial odds respectively exceed the 95th and 90th percentiles of the *BP(1,1)* pre-study population equipoise distribution. If 21% additional study participants were to be enrolled with no delay to study readout, Table 2 shows that power would be increased up to 95%. In this case the study outcome provides strong equipoise imbalance at the 95% percentile of the *BP(1,1)* equipoise distribution regardless of whether the outcome is positive or negative. Demonstrating strong equipoise imbalance in favour of the null hypothesis is a valuable result in practice, as a basis to discourage unnecessary future repetitions of trials unlikely to deliver positive results.

The bottom row in Table 2 also shows that further raising power of the primary study outcome up to 99% provides marginally stronger positive evidence and much stronger negative evidence against pre-study equipoise. However, recruitment of 69% additional study participants required to achieving 99% power in practice would likely entail substantial delays to study read-out coupled with more modest hazard ratio critical values, suggesting that achieving 99% power is not a promising avenue to improving design robustness.

Power	N (%)	HR CV		$r_{10}(+)$		$r_{01}(-)$	
		IA	FA	IA	FA	FA	
90%	680 (100%)	0.73	0.81	43.3	19.7	9.5	
95%	826 (121%)	0.75	0.82	50	20.8	19.1	
99%	1146 (169%)	0.79	0.85	59.7	21.7	95.4	

Table 2: power, sample size, hazard ratio critical values at 5% FWER and associated post-study odds using OBF alpha spending for a GS design assuming a TTE median of 10 months in the SOC arm and a 30% relative risk reduction in the investigational arm.

3 Equipoise calibration of clinical development plans

A recent review of late phase oncology clinical trials [29] examined the association between the level of pre-study evidence and the primary outcome of confirmatory studies in gastro-

intestinal cancers published between the year 2000 and 2020. Within the subset of phase 3 trials preceded by a phase 2 study designed to formally assess a pre-specified hypothesis, the phase 3 success rate for studies preceded by a positive phase 2 was roughly twice as large as for studies preceded by a negative phase 2 (41.9% vs 18.9%). This result suggests that joint design of both phase 2 and phase 3 studies within one clinical development plan (CDP, [30]) is relevant to optimise the probability of success of oncology confirmatory trials in these indications. Hence, the CDP design considered here comprises the design of one randomised phase 2 trial and one phase 3 confirmatory trial. To this end, (A.3)-(A.6) in the Appendix define post-study odds associated to the four possible CDP outcomes. Specifically, (A.5) represents the combined odds $r_{10}(+_2, +_3)$ in favour of the phase 2 and phase 3 trial hypotheses $(H_{1,2}, H_{1,3})$ upon observing positive outcomes in both studies. Similarly, (A.6) represents the odds in favour of the combined null hypotheses $(H_{0,2}, H_{0,3})$ if the mixed outcome $(+_2, -_3)$ were to be observed, labelled as $r_{01}(+_2, -_3)$. Equations (A.7)-(A.8) respectively define the post-study odds $r_{10}(-2, +3)$ and $r_{10}(-2, -3)$, which quantify the relative evidence in favour of the combined alternative $(H_{1,2}, H_{1,3})$ and of the combined null $(H_{0,2}, H_{0,3})$. These two cases are considered here because, as shown in [29], in practice a phase 3 trial may follow a negative phase 2 study, for instance based on a favourable phase 2 safety profile together with a perceived lack of association between phase 2 and phase 3 efficacy endpoints.

3.1 Equipoise calibration of CDP designs requires a between-study assumption

Equipoise calibration based on (A.3)-(A.6) guides the determination the CDP sample size and its distribution between phase 2 and phase 3 trials primarily to ensure that positive outcomes demonstrate strong equipoise imbalance in favour of the overall alternative $(H_{1,2}, H_{1,3})$ and to quantify the level of equipoise imbalance in favour of $(H_{0,2}, H_{0,3})$ associated with negative outcomes. Note here that a third assumption is needed beyond (1)-(2) to define the population distribution of pre-trial odds under equipoise when multiple studies are planned together. Similarly to (1)-(2), independence is used here to define joint pre-study equipoise as this assumption encodes the least background information. Under this joint equipoise model, Table 3 shows that the combined odds threshold 66:1 defines a CDP design appropriate to establishing overall equipoise imbalance from both phase 2 and phase 3 outcomes at the 95% percentile of the equipoise distribution.

Joint BP(1,1) model percentiles 50% 80% 85% 90% 95% 97.5%					99%
Odds Threshold		24	66	167	

 Table 3: 50%-99% percentiles of the independence BP(1,1) equipoise model for calibration of 2-trials CDPs.

3.2 Equipoise calibration of an oncology 2-study CDP

The primary objective of the phase 2 design here is to provide a robust go/no-go decision based on the observed difference between the proportions of patients alive and at risk of progression at 9 months follow-up (PFS9) randomised 1:1 to parallel investigational and SOC arms. The phase 2 design hypothesis is $H_{1,2}$: $PFS9_{inv} = 75\%$, $PFS9_{soc} = 55\%$ and the primary analysis outcome is defined positive if the p-value of the chi square statistic of the observed PFS9 difference is less than 0.05 at the pre-planned final analysis. The phase 3 design illustrated in Section 2 is used also for CDP design here, with primary endpoint based on overall survival (OS) [31]. Table 4 summarises the statistical properties and sample sizes of five CDP designs, ranging from a minimal option enrolling approximately 630 patients in total up to robust options enrolling up to almost 1600 patients. The phase 3 FWER is set at 5% for all but the most robust CDP option in Table 4, which sets the FWER at 1%. The CDPs labelled "Minimal" and "Upfront" in Table 4 comprise a relatively small phase 3 design (N=526 participants) preceded by either a small ($N \sim 100$) or larger ($N \sim 200$) phase 2 study. The columns on the right in Table 4 show that the level of overall equipoise imbalance in favour of $(H_{1,2}, H_{1,3})$ provided by two positive trials under these two options is strong, as $r_{10}(+_2, +_3)$ 140 \gg 66. However, evidence in favour of $(H_{0,2}, H_{0,3})$ associated to a mixed outcome here is insufficient, as $r_{01}(+_{2}, -_{3}) < 1$. This result is surprising, as the negative outcome of the larger phase 3 trial may be expected to dominate the overall equipoise imbalance. This is not the case due to the positive evidence from phase 2 being stronger than the negative evidence from phase 3 so that, when these are combined, the phase 2 outcome dominates the overall result. Specifically, the top two CDP designs in Table 4 are associated with a phase 3 negative likelihood ratio of $\frac{p(-3|H_{0,3})}{p(-1|H_{0,3})}$ $\frac{p(-3|H_{0,3})}{p(-3|H_{1,3})} = \frac{0.95}{0.2}$ $\frac{0.95}{0.2}$ = 4.75 and with a phase 2 positive likelihood ratio respectively equal to $\frac{p(+2|H_{0,2})}{p(+|H_{0,2})}$ $\frac{p(\pm 2|H_{0,2})}{p(\pm 2|H_{1,2})}$ = 0.1/0.8 = 0.125 and 0.05/0.9 \approx 0.055. Since the combined post-study odds for these two designs are $r_{01}(+_{2}, -_{3}) \le 4.75 \times 0.125 \approx 0.6$, the overall evidence from the mixed outcome $(+_2, -_3)$ numerically favours the alternative $(H_{1,2}, H_{1,3})$ despite observing a negative outcome in the larger phase 3 trial. Hence, these two CDPs do not represent viable strategies from a statistical perspective. This is not the case for the CDP design labelled "Base" in Table 4, which comprises a phase 2 design carrying 80% power at 10% false positive rate, followed by a phase 3 trial design with 90% cumulative power at 5% FWER. Of note, the "Base" strategy involves but a modest increase in sample size compared to the "Upfront" option. This "Base" CDP design provides strong equipoise imbalance when two

positive outcomes are observed, as $r_{10}(+_{2}, +_{3}) > 158 \gg 66$, weak evidence in favour of the overall null hypothesis when the phase 3 trial is negative $(r_{01}(+_{2}, -_{3}) = 1.2)$ and evidence in favour of the combined null abode the 90% percentile of the joint equipoise model (Table 3) when both phase 2 and phase 3 studies are negative $(r_{01}(-2, -3) = 43)$. The weak level of negative evidence associated to the mixed outcome $(+_2, -_3)$ for the "Base" design suggests an opportunity to explore stronger CDP strategies, which are represented in Table 4 by the "Robust" designs. These two options respectively consider raising the phase 3 power to 95% and then up to 99% together with a lower FWER of 1%. Both these robust designs provide strong evidence of equipoise imbalance when the phase 2 and phase 3 studies are positive $(r_{10}(+_{2}, +_{3}) \ge 167 \gg 66)$ or when the two studies are negative $(r_{01}(-_{2}, -_{3}) \ge 86 > 66)$. Of note, the top design in Table 4, carrying 80% power at 10% false positive rate in phase 2 and 95% cumulative power at 5% FWER in phase 3, is the smallest CDP design option ensuring that either double positive or double negative trial outcomes enable rejecting pre-CDP equipoise at the 95th percentile of the pre-study joint equipoise distribution shown in Table 3. Finally, the bottom row in Table 4 shows that equipoise imbalance in favour of the combined null exceeds the 80% percentile of the equipoise distribution in Table 3 upon observing the mixed CDP outcome $(+_2, -_3)$ only for the most robust design $(r_{01}(+_2, -_3) = 12.4)$. However, the stronger evidence provided by a mixed outcome of a very robust CDP design is unlikely to outweigh the operational complexity and substantial extension to study read-out times entailed by recruitment of over 600 additional participants.

Table 4: characteristics of clinical development plan designs comprising one phase 2 trial and one phase 3 trial. The designs labelled "Minimal" and "Upfront" deliver strong equipoise imbalance if both trials are positive, but insufficient evidence against the join null if the phase 3 trial fails to confirm a positive phase 2 outcome. The "Base" case delivers numerical evidence against the joint null in the mixed outcome case $(+_2, -_3)$. *The two "Robust" options further increase the levels of equipoise imbalance by recruiting respectively 19% and 100% additional study participants compared to the "Base" case. The top robust design is the smallest CDP delivering strong equipoise imbalance when double positive or double negative outcomes are observed in the phase 2 and phase 3 studies.*

Discussion

Equipoise calibration is introduced above as a design method mitigating potential gaps between statistically significant and clinically meaningful clinical trial outcomes. Under the least informative clinical equipoise distribution, the level of equipoise imbalance provided by positive trial outcomes at traditional levels of operating characteristics was shown to be substantial. Increasing power up to 95% was identified as an avenue for negative trial outcomes to achieve the same evidence level, which is relevant in practice when a negative study outcome is to inform specific subsequent development plans. In oncology, for instance, investigational agents are typically developed in phase 3 trials first as monotherapy and then in combination. Here equipoise calibration provides a simple method to determining the operational characteristics of the first phase 3 trial to ensure that a negative outcome provides sufficient evidence to discontinue further development, in absence of evidence of synergistic interactions with combination partners. The study of the potential impact of applying equipoise calibration in these specific circumstances lies beyond the scope of this paper and provides a topic for further research.

The equipoise models explored here are also amenable to being further developed if definitions of equipoise were to emerge, beyond 1:1 median or mean pre-study odds, or if the principle of maximum entropy were not found to be sufficient for design calibration in specific practical circumstances. One such instance pertains to a lack of perfect equipoise, which may emerge in practice when external trials report results thought of as being predictive of the outcome of a phase 3 being planned. As much as this situation is common in practice, especially when multiple sponsors concurrently develop similar compounds, it is not clear yet when and to what extent lack of perfect pre-study equipoise may be taken as a starting point for design and analysis of new randomised trials to effectively accelerate clinical development. In these circumstances, equipoise calibration provides a framework to calculate the design operating characteristics needed to achieve an overall level of strong equipoise imbalance from pre-trial odds other than 1:1. The study of specific circumstances where these designs may be successful in practice provides a second topic for further research.

Appendix: formal definitions of post study odds

Using the odds form of Bayes theorem, the post-study odds of a randomised clinical trial with null hypothesis H_0 and alternative H_1 are defined as

$$
r_{10}(+) := \frac{P(H_1|+)}{P(H_0|+)} = \frac{P(H_1)}{P(H_0)} \times \frac{p(+|H_1)}{p(+|H_0)},
$$
\n
$$
r_{01}(-) := \frac{P(H_0|-)}{P(H_1|-)} = \frac{P(H_0)}{P(H_1)} \times \frac{p(-|H_0)}{p(-|H_1)}.
$$
\n(A.2)

The right-hand side of equation (A.1) represents the ratio of the probabilities of the alternative hypothesis based on the pre-study probability ratio $\frac{P(H_1)}{P(H_2)}$ $\frac{P(H_1)}{P(H_0)}$ and on observing a positive study outcome associated with pre-specified power $p(+|H_1)$ and false positive rate $p(+|H_0)$. Equation $(A.2)$ represents the ratio of the probabilities of the null hypothesis based on the same pre-study evidence and on a negative study outcome.

The overall post-study odds of this CDP design are analogously defined as:

$$
r_{10}(+_{2},+_{3}) := \frac{P(H_{1,2},H_{1,3}|+_{2},+_{3})}{P(H_{0,2},H_{0,3}|+_{2},+_{3})} = \frac{P(H_{1,2},H_{1,3})}{P(H_{0,2},H_{0,3})} \times \frac{p(+_{2}|H_{1,2})}{p(+_{2}|H_{0,2})} \times \frac{p(+_{3}|+_{2},H_{1,3})}{p(+_{3}|+_{2},H_{0,3})},
$$
(A.5)

$$
r_{01}(+_{2},-_{3}) := \frac{P(H_{0,2},H_{0,3}|+_{2},-_{3})}{P(H_{1,2},H_{1,3}|+_{2},-_{3})} = \frac{P(H_{0,2},H_{0,3})}{P(H_{0,2},H_{1,3})} \times \frac{p(+_{2}|H_{0,2})}{p(+_{2}|H_{1,2})} \times \frac{p(-_{3}|+_{2},H_{0,3})}{p(-_{3}|+_{2},H_{1,3})},
$$
(A.6)

$$
r_{10}(-_{2},+_{3}) := \frac{P(H_{1,2},H_{1,3}|-_{2},+_{3})}{P(H_{0,2},H_{0,3}|-_{2},+_{3})} = \frac{P(H_{1,2},H_{1,3})}{P(H_{0,2},H_{0,3})} \times \frac{p(-_{2}|H_{1,2})}{p(-_{2}|H_{0,2})} \times \frac{p(+_{3}|-_{2},H_{1,3})}{p(+_{3}|-_{2},H_{0,3})},
$$
(A.7)

$$
r_{01}(-_{2},-_{3}) := \frac{P(H_{0,2},H_{0,3}|-_{2},-_{3})}{P(H_{1,2},H_{1,3}|-_{2},-_{3})} = \frac{P(H_{0,2},H_{0,3})}{P(H_{0,2},H_{1,3})} \times \frac{p(-_{2}|H_{0,2})}{p(-_{2}|H_{1,2})} \times \frac{p(-_{3}|-_{2},H_{0,3})}{p(-_{3}|-_{2},H_{1,3})}.
$$
(A.8)

Declarations

This work was completed while the author was a full-time employee of AstraZeneca PLC, which consented to its publication. No dedicated funding was needed.

No external data were used beyond the publications reported in the References Section below.

The Author declares no competing interests. The Author wishes to acknowledge Dr Michael Sweeting, Dr Jason Clark and Dr Nicola Valeri for their comments to a previous version of this work.

No LLM support was used.

References

[1] ICH E9 - Statistical Principles for Clinical Trials CPMP/ICH/363/96 [1998]

[https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf)[5_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf)

[2] ICH E11A – Paediatric Extrapolation [2024]

https://database.ich.org/sites/default/files/ICH_E11A_Guideline_Step4_2024_0821.pdf

[3] ICH E20 – Adaptive Clinical Trials Working Group [2024]

https://database.ich.org/sites/default/files/E20_FinalConceptPaper_2019_1107_0.pdf

[4] ICH E22 – General Considerations for Patience Preference Studies Working Group [2024]

https://database.ich.org/sites/default/files/ICH_E22_ConceptPaper_2024_0602.pdf

[5] Leek J, McShane BB, Gelman A, Colquhoun D, Nuijten MB, Goodman SN. (2017) Five ways to fix statistics. Nature. Vol. 30;551(7682):557-559. doi: 10.1038/d41586-017-07522-z. PMID: 29189798

[6] Freedman, B. Equipoise and the ethics of clinical research. NEJM. 1987, 317:141-145

[7] Rigat F. (2024). A conservative approach to leveraging external evidence for effective clinical trial design. Pharm. Stat. Vol. 23(1):81‐90. doi:10.1002/pst.233990

[8] Benjamin, D.J., Berger, J.O., Johannesson, M. et al. (2018). Redefine statistical significance. Nat Hum Behav 2, 6–10.<https://doi.org/10.1038/s41562-017-0189-z>

[9] ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials

EMA/CHMP/ICH/436221/2017 [2020] [https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-5_en.pdf) [addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-5_en.pdf)[5_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-5_en.pdf)

[10] Eisenhauer EA, et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. Vol. 45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. PMID: 19097774.

[11] Hodi FS, et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. J Clin Oncol. 2018 Mar 20;36(9):850-858. doi: 10.1200/JCO.2017.75.1644. Epub 2018 Jan 17. PMID: 29341833.

[12] Platzbecker U, et al. (2019). Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood. Vol. 7;133(10):1020-1030. doi: 10.1182/blood-2018-06-857102. Epub 2018 Nov 7. PMID: 30404811; PMCID: PMC7042664.

[13] Cheson BD, et al. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. Vol. 20;32(27):3059-68. doi: 10.1200/JCO.2013.54.8800. PMID: 25113753; PMCID: PMC4979083.

[14] Cheson BD, et al. (2003). Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. Vol.15;21(24):4642-9. doi: 10.1200/JCO.2003.04.036. PMID: 14673054

[15] Durie BG, et al. (2006). International uniform response criteria for multiple myeloma. Leukemia. Vol. 20(9):1467-73. doi: 10.1038/sj.leu.2404284. Epub 2006 Jul 20. PMID: 16855634.

[16] Paiva B, van Dongen JJ, Orfao A. (2015). New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015 May 14;125(20):3059-68. doi: 10.1182/blood-2014-11-568907. PMID: 25838346; PMCID: PMC4513329.

[17] ICH E6 (R2) Good clinical practice - Scientific guideline [2017[\] https://www.ema.europa.eu/en/ich-e6-r2](https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice-scientific-guideline) [good-clinical-practice-scientific-guideline](https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice-scientific-guideline)

[18] Asonganyi Folefac C, Desmond H. (2024). Clinical equipoise: Why still the gold standard for randomized clinical trials? Clinical Ethics. Vol.19(1):102-112. doi:10.1177/14777509221121107

[19] Sotorasib for KRAS G12C Mutated Locally Advanced or Metastatic NSCLC - FDA Oncologic Drugs Advisory Committee Meeting [2023[\] https://www.fda.gov/media/172756/download](https://www.fda.gov/media/172756/download)

[20] Tito Fojo, Meredith LaRose, Susan E Bates (2024). The Impact of Exuberance on Equipoise in Oncology Clinical Trials: Sotorasib as Archetype. The Oncologist, Vol, 29: 4, pp 275–277, <https://doi.org/10.1093/oncolo/oyae042>

[21] Johnson N, Lilford RJ, Brazier W. (1991). At what level of collective equipoise does a clinical trial become ethical? *Journal of Medical Ethics* Vol. 17:30-34

[22] Gosling, J.P. (2018). SHELF: The Sheffield Elicitation Framework. In: Dias, L., Morton, A., Quigley, J. (eds) Elicitation. International Series in Operations Research & Management Science, vol 261. Springer, Cham. https://doi.org/10.1007/978-3-319-65052-4_4

[23] Sindhu R. J, et al. (2010). Methods to elicit beliefs for Bayesian priors: a systematic review. Journal of Clinical Epidemiology, Vol. 63:4

[24] Jaynes ET. On the rationale of maximum-entropy methods. (1982). IEEE Proceedings, Vol.70(9):939-52. [25] Gelman, Andrew. (2009). Bayes, Jeffreys, Prior Distributions and the Philosophy of Statistics. Statistical Science, Vol. 24:2, pp. 176–78.<http://www.jstor.org/stable/25681293>

[26] Jose M. Bernardo (1979). Reference Posterior Distributions for Bayesian Inference, Journal of the Royal Statistical Society: Series B (Methodological), Vol. 41:2, pp 113–128,

[27] Jennison, Christopher, and Turnbull, Bruce W. (1999) Group Sequential Methods with Applications to Clinical Trials. United States, CRC Press

[28] Wassmer, G. and Brannath W. (2016) Group Sequential and Confirmatory Adaptive Designs in Clinical Trials. Springer Series in Pharmaceutical Statistics, ISBN 978-3-319-32560-6

[29] Bregni, G. et al. (2023). Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review, *JNCI: Journal of the National Cancer Institute*, Vol. 115:5, pp. 505- 513, <https://doi.org/10.1093/jnci/djad030>

[30] ICH guideline E8 (R1) on general considerations for clinical studies [2022] [https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-8-general-considerations-clinical-trials](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-8-general-considerations-clinical-trials-step-5_en.pdf)[step-5_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-8-general-considerations-clinical-trials-step-5_en.pdf)

[31] Shahnam A, et al. (2023) Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies. Eur J Cancer. Feb;198:113503. doi: 10.1016/j.ejca.2023.113503. PMID: 38134560.